Pharmacokinetic changes related to acute infection. Examples from the SARS-CoV-2 pandemic
Copyright © 2020 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved..
The knowledge of factors of pharmacokinetic variability is important in order to personalize pharmacological treatment, particularly for drugs with a narrow therapeutic range for which pharmacological therapeutic monitoring is recommended. Inflammation is a protective response against acute infections and injuries that contributes to intra- and inter-individual variability in drug exposure by modulating the activity of enzymes involved in drug metabolism, and by altering the binding of drugs to plasma proteins. The understanding of the impact of inflammation on drug metabolism and the related clinical consequences allow to better take into consideration the effect of inflammation on the variability of drug exposure. We first summarized the molecular mechanisms by which inflammation contributes to the inhibition of drug metabolism enzymes. We then presented an updated overview of the consequences of the outcome of acute infectious event on pharmacokinetic exposure of drugs with a narrow therapeutic range and that are substrates of cytochrome P450, and the related clinical consequences. Finally, in the context of the COVID-19 pandemic, we reported examples of drug overexposures in COVID- 19 infected patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Therapie - 76(2021), 4 vom: 25. Juli, Seite 319-333 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Modifications pharmacocinétiques liées à une infection aiguë. Exemples issus de la pandémie de SARS-CoV-2 |
|---|
| Beteiligte Personen: |
Chavant, Anaëlle [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 31.08.2021 Date Revised 31.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.therap.2020.10.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316979708 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316979708 | ||
| 003 | DE-627 | ||
| 005 | 20231225162246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.therap.2020.10.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM316979708 | ||
| 035 | |a (NLM)33129512 | ||
| 035 | |a (PII)S0040-5957(20)30182-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Chavant, Anaëlle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetic changes related to acute infection. Examples from the SARS-CoV-2 pandemic |
| 246 | 3 | 3 | |a Modifications pharmacocinétiques liées à une infection aiguë. Exemples issus de la pandémie de SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2021 | ||
| 500 | |a Date Revised 31.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a The knowledge of factors of pharmacokinetic variability is important in order to personalize pharmacological treatment, particularly for drugs with a narrow therapeutic range for which pharmacological therapeutic monitoring is recommended. Inflammation is a protective response against acute infections and injuries that contributes to intra- and inter-individual variability in drug exposure by modulating the activity of enzymes involved in drug metabolism, and by altering the binding of drugs to plasma proteins. The understanding of the impact of inflammation on drug metabolism and the related clinical consequences allow to better take into consideration the effect of inflammation on the variability of drug exposure. We first summarized the molecular mechanisms by which inflammation contributes to the inhibition of drug metabolism enzymes. We then presented an updated overview of the consequences of the outcome of acute infectious event on pharmacokinetic exposure of drugs with a narrow therapeutic range and that are substrates of cytochrome P450, and the related clinical consequences. Finally, in the context of the COVID-19 pandemic, we reported examples of drug overexposures in COVID- 19 infected patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Drug metabolism | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Métabolisation | |
| 650 | 4 | |a Pharmacocinétique | |
| 650 | 4 | |a Pharmacokinetics | |
| 650 | 4 | |a Suivi thérapeutique pharmacologique | |
| 650 | 4 | |a Therapeutic drug monitoring | |
| 700 | 1 | |a Gautier-Veyret, Elodie |e verfasserin |4 aut | |
| 700 | 1 | |a Chhun, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Guilhaumou, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Stanke-Labesque, Françoise |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapie |d 1947 |g 76(2021), 4 vom: 25. Juli, Seite 319-333 |w (DE-627)NLM000023655 |x 1958-5578 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2021 |g number:4 |g day:25 |g month:07 |g pages:319-333 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.therap.2020.10.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2021 |e 4 |b 25 |c 07 |h 319-333 | ||